Skip to main content

RA Capital Management — Portfolio, Page 17

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
24
Industries
Biotechnology 22Health Care 14Therapeutics 10Medical 8Life Science 7Pharmaceutical 6+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 385408 of 453
Cerevel Therapeutics
October 2023

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Biotechnology · Boston$450.0M Post Ipo Equity
Adela
September 2023

Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.

Biotechnology · Foster City$48.0M Series A
Hyku
September 2023

Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.

Biopharma · Lexington$56.0M Seed
Mariana Oncology
September 2023

Mariana Oncology is a biotechnology research industry.

Bioinformatics · Watertown$175.0M Series B
ExcepGen
August 2023

RNA based vaccines with tolerability close to the standard of care by dampening an excessive innate immune response

Biopharma · San Francisco$4.0M Seed
Gracell Biotechnologies
August 2023

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

Biotechnology · Suzhou$100.0M Post Ipo Equity
Inozyme
July 2023

Inozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.

Biotechnology · Boston$60.0M Post Ipo Equity
Ocelot Bio
July 2023

Ocelot Bio brings new treatment options to patients with severe liver disease.

Biotechnology · San Diego$3.0M Debt Financing
Septerna
July 2023

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

Biotechnology · San Francisco$150.0M Series B
Aeglea BioTherapeutics
June 2023

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Biotechnology · Austin$210.0M Post Ipo Equity
Pluton Biosciences
May 2023

Pluton Biosciences tests and discovers microbes for the production of a variety of products, primarily pesticides, and pharmaceuticals.

AgTech · Saint Louis$16.5M Series A
Icosavax
May 2023

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Biotechnology · Seattle$67.8M Post Ipo Equity
Boundless Bio
May 2023

Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.

Biotechnology · La Jolla$100.0M Series C
Legend Biotech
May 2023

Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.

Biotechnology · Piscataway$350.0M Post Ipo Equity
Ventus Therapeutics
April 2023

Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.

Biotechnology · Waltham$150K Grant
Capacity Bio
March 2023

Capacity Bio is a therapeutics company that is focused on mitophagy.

Biotechnology · Palo Alto$35.0M Series A
TeraPore Technologies
March 2023

TeraPore Technologies is a Cornell University spinout that develops and manufactures high performance filters for protein separations.

Biofuel · South San Francisco$10.0M Series Unknown
Avilar Therapeutics
February 2023

Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.

Biotechnology · Waltham$15.0M Seed
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
Jnana Therapeutics
November 2022

Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.

Biotechnology · Boston$107.0M Series C
Spero Therapeutics
September 2022

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.

Biotechnology · Cambridge$9.0M Post Ipo Equity
Point Biopharma
September 2022

Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.

Biopharma · Indianapolis$125.0M Post Ipo Equity
Empatica
August 2022

Empatica is an affective computing company focused on human data analytics.

Artificial Intelligence (AI) · Cambridge$25.9M Series B
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant

Where RA Capital Management invests

Biotechnology22
Health Care14
Therapeutics10
Medical8
Life Science7
Pharmaceutical6

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 24 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Cerevel Therapeutics received $450.0M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Cerevel Therapeutics, Adela, Hyku, Mariana Oncology, ExcepGen. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →